title: Novel Therapies for Eosinophilic Disorders.
abstract: Current therapies for eosinophilic disorders are limited. Most treatment approaches remain empirical, are not supported by data from controlled clinical trials, involve the off-label use of agents developed for treatment of other diseases, and tend to rely heavily on the use of glucocorticoids and other agents with significant toxicity. Great progress has been made in the discovery, preclinical development, and clinical testing of a variety of biologics and small molecules that have the potential to directly or indirectly influence eosinophils, eosinophilic inflammation, and the consequences of eosinophil activation.
authors.affiliation: Division of Allergy-Immunology, Department of Medicine, Northwestern University Feinberg School of Medicine, 240 East Huron Street, Room M-306, Chicago, IL 60611, USA. Electronic address: bruce.bochner@northwestern.edu.
authors.forename: Bruce S
authors.initials: BS
authors.lastname: Bochner
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy* / Q000473:pathology; D016207:Cytokines / Q000037:antagonists & inhibitors; D004804:Eosinophils / Q000187:drug effects / Q000473:pathology; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D017681:Hypereosinophilic Syndrome / Q000188:drug therapy* / Q000473:pathology; D058990:Molecular Targeted Therapy / Q000379:methods*; D011956:Receptors, Cell Surface / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D016207:Cytokines; D005938:Glucocorticoids; D011956:Receptors, Cell Surface
keywords: Antibodies; Biomarkers; Eosinophil; Pharmacology; Targets; Therapies